Concordia Healthcare Corp. (NASDAQ:CXRX)’s share price dropped 4.9% during trading on Friday . The company traded as low as $19.39 and last traded at $19.47, with a volume of 192,840 shares traded. The stock had previously closed at $20.47.

CXRX has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Concordia Healthcare Corp. from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Wednesday, July 13th. Laurentian Bank of Canada dropped their target price on shares of Concordia Healthcare Corp. from $60.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, March 28th. CIBC increased their target price on shares of Concordia Healthcare Corp. from $31.00 to $34.00 and gave the stock a “sector performer” rating in a research report on Tuesday, March 29th. Laurentian reiterated a “buy” rating and set a $55.00 target price (down previously from $60.00) on shares of Concordia Healthcare Corp. in a research report on Thursday, March 31st. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $73.50 target price (down previously from $81.00) on shares of Concordia Healthcare Corp. in a research report on Saturday, April 23rd. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $48.88.

The company’s market capitalization is $993.28 million. The firm’s 50 day moving average is $22.07 and its 200-day moving average is $27.19.

Concordia Healthcare Corp. (NASDAQ:CXRX) last announced its earnings results on Friday, May 13th. The company reported $1.35 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.54 by $0.19. The firm had revenue of $228.50 million for the quarter, compared to the consensus estimate of $231 million. Concordia Healthcare Corp.’s revenue was up 570.1% on a year-over-year basis. On average, equities analysts forecast that Concordia Healthcare Corp. will post $6.17 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Friday, July 15th will be given a dividend of $0.075 per share. The ex-dividend date of this dividend is Wednesday, July 13th. This represents a $0.30 annualized dividend and a yield of 1.54%.

A number of large investors have recently bought and sold shares of CXRX. Swiss National Bank boosted its stake in Concordia Healthcare Corp. by 26.7% in the fourth quarter. Swiss National Bank now owns 49,810 shares of the company’s stock valued at $2,031,000 after buying an additional 10,510 shares in the last quarter. Thornburg Investment Management Inc. boosted its stake in Concordia Healthcare Corp. by 48.3% in the fourth quarter. Thornburg Investment Management Inc. now owns 116,235 shares of the company’s stock valued at $4,746,000 after buying an additional 37,847 shares in the last quarter. ProShare Advisors LLC purchased a new stake in Concordia Healthcare Corp. during the fourth quarter valued at $1,671,000. Morgan Stanley boosted its stake in Concordia Healthcare Corp. by 24.6% in the fourth quarter. Morgan Stanley now owns 269,768 shares of the company’s stock valued at $11,015,000 after buying an additional 53,305 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Concordia Healthcare Corp. during the fourth quarter valued at $2,419,000.

Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc, which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran (zonisamide), for treatment of partial seizures in adults with epilepsy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.